Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
128M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
63.4M
-
Shares change
-
+985K
-
Total reported value, excl. options
-
$2.72B
-
Value change
-
+$19.9M
-
Put/Call ratio
-
0.4
-
Number of buys
-
78
-
Number of sells
-
-79
-
Price
-
$42.91
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q1 2021
200 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q1 2021.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.4M shares
of 128M outstanding shares and own 49.63% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (10.5M shares), VANGUARD GROUP INC (6.1M shares), BlackRock Inc. (5.89M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (4.56M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.64M shares), JENNISON ASSOCIATES LLC (2.71M shares), STATE STREET CORP (2.2M shares), Farallon Capital Management, L.L.C. (2.18M shares), VICTORY CAPITAL MANAGEMENT INC (1.93M shares), and Cormorant Asset Management, LP (1.87M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.